June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
High CAE Responders Show Greater Improvement in Signs and Symptoms of Dry Eye after Treatment with MIM-D3
Author Affiliations & Notes
  • George Ousler
    Ora, Inc., Andover, MA
  • Karen Meerovitch
    Mimetogen Pharmaceuticals, Montreal, QC, Canada
  • Footnotes
    Commercial Relationships George Ousler, Ora, Inc. (E); Karen Meerovitch, Mimetogen Pharmaceuticals, Inc. (E), Mimetogen Pharmaceuticals, Inc. (P)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4343. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      George Ousler, Karen Meerovitch; High CAE Responders Show Greater Improvement in Signs and Symptoms of Dry Eye after Treatment with MIM-D3. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4343.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: This post-hoc subset analysis was performed on data from a completed clinical trial of MIM-D3 Ophthalmic Solution in dry eye (Invest Ophthalmol Vis Sc 2012 53:E-Abstract) to explore differences in treatment effect when patients were stratified by baseline severity of response to a Controlled Adverse Environment (CAE). It was hypothesized that patients with greater staining or more rapid symptomatic responses to the CAE at baseline would predict which patients would react more favorably and with greater magnitudes of change to treatment with MIM-D3.

Methods: A 2-center, randomized, double-masked, placebo-controlled Phase 2 study was conducted in 150 dry eye patients. Key eligibility criteria included scores of ≥ 4, ≥ 2 and ≥ 2 for fluorescein corneal staining (FCS), lissamine green staining, and one symptom from the 4-Symptom Questionnaire. Patients also had to positively respond to CAE exposure on 2 visits with exacerbation of FCS and ocular discomfort. Eligible patients dosed BID with 1% MIM-D3, 5% MIM-D3 or placebo for 28 days and recorded symptoms in diaries. Efficacy measures were FCS post-CAE at Day 28 and diary data for the 28-day period. A post-hoc analysis separated patients by mild, moderate or severe FSC after a baseline pre to post CAE assessment. A second stratification was for time: less than or greater than 20 minutes in the CAE to reach maximal ocular discomfort. The outcome of interest was mean change in FSC from pre- to post-CAE at day 28.

Results: A dramatic difference in treatment effect was observed when patient’s baseline CAE responses were stratified by mild, moderate and severe. Mean change from baseline FCS scores in the 1% MIM-D3 dosed group went from a -1.08 unit treatment difference to placebo (P <0.05) in the severe responders to only a -0.06 unit change in the mild responders. Similarly, patients who were hyper responsive to the CAE in symptomatology showed a greater improvement in FCS than slow responders, driving the observed ITT effect.

Conclusions: These post-hoc data support the hypothesis that patients with a greater or more rapid exacerbation of signs and symptoms from environmental challenges such as the CAE, are more responsive to a drug like MIM-D3, which targets mucin-protective compensatory mechanisms that turn on during an adverse challenge.

Keywords: 486 cornea: tears/tear film/dry eye • 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 485 cornea: surface mucins  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.